To investigate the clinical effect of inhaled ribavirin on the therapeutic actions and the expression of interleukin 6(IL-6), interleukin 10(IL-10)and CysLTs in children with RSV bronchitis.

81 cases of children with RSV bronchitis, were chosen and randomly divided into observing group and control group. Two groups of children were inhaled pulmicort respulas and accessed others support treatment, until the symptoms disappeared. But observing group were added with ribavirin atomization. Treatments time and symptoms disappearance time in the hospital were compared, and the serum IL-6,IL-10 and CysLTs level changes before and after treatment were observed.

Treatments time and symptoms(wheezing, coughing, dry and wet rale)disappearance time in observation group were shorter than those of the control group with(6.58±1.36)d vs.(8.92±1.12)d,(1.21± 0.59)d vs. (2.68±1.22)d,(4.86±1.31)d vs.(7.34±1.39)d and(4.00±1.52)d vs.(6.37±1.58)d, which with significant differences(t＝-8.387,-7.012,-8.267,-6.887,all P＜0.01). Before the treatment, two groups had no significant difference(P＞0.05). After treatment, the levels of serum IL-6 and CysLTs were significantly lower in the observation group, and the levels of IL-10 were higher with(76.59±10.77)ng／L vs.(116.81±10.81)ng／L,(34.40±7.19)ng／mL vs.(48.26±8.36)ng／mL and,(43.25±3.97)ng／L vs.(31.39± 4.81)ng／L. The significant differences were observed in two groups(t＝-16.74,-8.024,12.315,all P＜0.05).

Compared with general therapy, the curative effect was significant. Combined inhaled ribavirin and pul-micort respulas in RSV bronchitis early, can reduce patients'clinical symptoms and the treatment time.

Respiratory syncytial virus; Bronchiolitis; Ribavirin